Is there Evidence to Support the use of Enteric Coated (EC) Aspirin to Reduce Gastrointestinal Side Effects in Cardiovascular Patients?

Publisher: London and South East Regional Medicines Information Service

Date published: 23/09/2011 15:52

Review date: 31/03/2013 15:30

Summary

by: Sonal Patel

This meds Q&A reviews the evidence surrounding the use of enteric coated aspirin to prevent gastrointestinal damage, and also the effect of enteric coating on the antiplatelet effect of aspirin therapy.

About this library entry

Category: 2.9 Antiplatelet drugs | Cardiovascular Medicine | FAQs | Peptic Ulceration | Pharmaceutics

NeLM area: Evidence > Medicines Q & A

Med_QA_aspirin_EC_Finaldp.doc

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.

Printer Friendly Version

Related evidence

2.9 Antiplatelet drugs

26/10/2011

NICE issues guidance on ticagrelor for the treatment of acute coronary syndromes (ACS) – TA 236

01/08/2011

NICE issues clinical guideline for the management of stable angina

15/06/2011

MTRAC review: Ticagrelor for the treatment of acute coronary syndromes

Cardiovascular Medicine

23/05/2012

NICE TA 256: Rivaroxaban for the prevention of stroke and systemic

27/04/2012

Preoperative statin therapy for patients undergoing cardiac surgery

15/03/2012

NICE issues guidance on dabigatran etexilate for prevention of stroke and systemic embolism in AF

Peptic Ulceration

26/03/2010

Epinephrine injection versus epinephrine injection and a second endoscopic method in high risk bleeding ulcers

28/07/2009

CKS Topic Review: Antiplatelet treatment

23/09/2008

Upper gastrointestinal complications among users of paracetamol

Back

Search the NeLM

Medicines A-Z

Preview your comment

Add new comment

Comments